Department of Pathology, University of Washington, Seattle, WA 98109, USA.
Department of Neurology, University of Washington, Seattle, WA 98195, USA.
Cell Rep. 2020 Jun 2;31(9):107719. doi: 10.1016/j.celrep.2020.107719.
SORL1/SORLA is a sorting receptor involved in retromer-related endosomal traffic and an Alzheimer's disease (AD) risk gene. Using CRISPR-Cas9, we deplete SORL1 in hiPSCs to ask if loss of SORL1 contributes to AD pathogenesis by endosome dysfunction. SORL1-deficient hiPSC neurons show early endosome enlargement, a hallmark cytopathology of AD. There is no effect of SORL1 depletion on endosome size in hiPSC microglia, suggesting a selective effect on neuronal endosomal trafficking. We validate defects in neuronal endosomal traffic by showing altered localization of amyloid precursor protein (APP) in early endosomes, a site of APP cleavage by the β-secretase (BACE). Inhibition of BACE does not rescue endosome enlargement in SORL1-deficient neurons, suggesting that this phenotype is independent of amyloidogenic APP processing. Our data, together with recent findings, underscore how sporadic AD pathways regulating endosomal trafficking and autosomal-dominant AD pathways regulating APP cleavage independently converge on the defining cytopathology of AD.
SORL1/SORLA 是一种参与内体相关的逆向运输的分选受体,也是阿尔茨海默病(AD)的风险基因。我们使用 CRISPR-Cas9 技术在 hiPSCs 中敲除 SORL1,以探讨 SORL1 的缺失是否通过内体功能障碍导致 AD 发病。SORL1 缺陷的 hiPSC 神经元表现出早期内体增大,这是 AD 的一个标志性细胞病理学特征。SORL1 缺失对 hiPSC 小胶质细胞内体大小没有影响,这表明其对神经元内体运输具有选择性影响。我们通过显示 APP 在早期内体中的定位改变(APP 是由β-分泌酶(BACE)切割的部位),证实了神经元内体运输的缺陷。抑制 BACE 并不能挽救 SORL1 缺陷神经元中的内体增大,这表明该表型与淀粉样前体蛋白(APP)的淀粉样生成过程无关。我们的数据以及最近的发现强调了散发性 AD 途径如何调节内体运输,以及常染色体显性 AD 途径如何独立调节 APP 切割,共同导致 AD 的标志性细胞病理学特征。